ad

3 Digital IT Services Company, Drug Research and Manufacturing Company and Jewellery Retailer Stocks With a Strong Future Roadmap: Happiest Minds Technologies, Anthem Biosciences and Kalyan Jewellers India

Happiest Minds Technologies, Anthem Biosciences and Kalyan Jewellers India: ROE of 12.6% to 21.4% and FY22 to FY26 revenue CAGR of 15.5% to 34.9%. Prices as of 16 Nov 2026.


17 Nov 2026 • 2:52 pm

3 Digital IT Services Company, Drug Research and Manufacturing Company and Jewellery Retailer Stocks With a Strong Future Roadmap: Happiest Minds Technologies, Anthem Biosciences and Kalyan Jewellers India

Quick Answer

The three digital IT, drug research and jewellery stocks to watch are Happiest Minds Technologies, Anthem Biosciences and Kalyan Jewellers India. Their return on equity ranges from 12.6% to 21.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.5% to 34.9%. Kalyan Jewellers India leads on both return on equity at 21.4% and revenue growth at 34.9% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.

Digital IT, drug research and jewellery stocks give investors a way to track businesses that sit close to everyday demand in India. Happiest Minds Technologies, Anthem Biosciences and Kalyan Jewellers India cover a digital IT services company, a drug research and manufacturing company and a jewellery retailer.

This list covers three digital IT, drug research and jewellery stocks with complete current figures: Happiest Minds Technologies, Anthem Biosciences and Kalyan Jewellers India. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Digital IT, Drug Research and Jewellery Stocks?

Digital IT, drug research and jewellery stocks are listed companies that build digital and cloud solutions for global clients, develop and manufacture drugs and biologics for pharma partners, and sell gold and diamond jewellery through large stores. Their earnings depend on client technology budgets, outsourced drug work and festive jewellery demand.

Digital IT, Drug Research and Jewellery Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Happiest Minds Technologies 308.5 4,680 21.0 17.9 12.6 0.88
Anthem Biosciences 931.45 45,546 79.1 36.0 19.4 0.02
Kalyan Jewellers India 708.15 52,898 36.9 44.3 21.4 0.97

On valuation, Kalyan Jewellers India trades at a P/E below the industry P/E, while Happiest Minds Technologies and Anthem Biosciences trade above it, which reflects the growth the market already expects. Readers comparing digital IT, drug research and jewellery stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Digital IT, Drug Research and Jewellery Stocks Have a Strong Roadmap in India?

Digital IT, drug research and jewellery stocks have a strong roadmap in India because rising digital projects, growing outsourcing of drug development and steady jewellery buying in festivals and weddings keep widening the market for these companies.

  • Digital services. Clients modernise their systems.
  • Drug research. Pharma firms outsource development work.
  • Jewellery. Families buy gold for weddings and festivals.

Why Happiest Minds Technologies Features Among These Digital IT, Drug Research and Jewellery Stocks

Among the digital IT, drug research and jewellery stocks on this list, Happiest Minds Technologies is a Bengaluru-based digital transformation company that offers product engineering, digital business services and generative artificial intelligence solutions to clients across industries.

In the June 2026 quarter, revenue grew 12.5% year on year to Rs 652 crore, while net profit rose 18.3% to Rs 67.6 crore. Revenue rose from Rs 1,131 crore in FY22 to Rs 2,400 crore in FY26, a compound annual growth rate of 20.7%.

Net profit grew from Rs 185 crore in FY25 to Rs 213 crore in FY26, a rise of 15.1%. The company has a return on equity of 12.6%, a debt to equity ratio of 0.88 and a market capitalisation of Rs 4,680 crore. The stock trades at a P/E of 21.0, above the industry P/E of 17.9.

Roadmap: The company is adding capabilities in artificial intelligence, cloud and cybersecurity, which enterprises are prioritising. A digital-first positioning helps it win newer projects from established clients.

What to watch: Track the mix of digital business and product engineering revenue and new client additions.

Why Anthem Biosciences Features Among These Digital IT, Drug Research and Jewellery Stocks

Among the digital engineering, contract research and gold jewellery shares on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0.

Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.

Roadmap: The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.

What to watch: Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.

Why Kalyan Jewellers India Features Among These Digital IT, Drug Research and Jewellery Stocks

Among the three companies on this list, Kalyan Jewellers India is a large jewellery retailer with showrooms across India and the Middle East, selling gold, diamond and studded jewellery under the Kalyan and Candere brands.

Revenue rose from Rs 10,856 crore in FY22 to Rs 35,951 crore in FY26, a compound annual growth rate of 34.9%. Net profit grew from Rs 224 crore in FY22 to Rs 1,350 crore in FY26, which works out to a compound annual growth rate of 56.7%.

In the June 2026 quarter, revenue grew 45.5% year on year to Rs 10,645 crore, while net profit rose 32.0% to Rs 349 crore. The company has a return on equity of 21.4%, a debt to equity ratio of 0.97 and a market capitalisation of Rs 52,898 crore. The stock trades at a P/E of 36.9, below the industry P/E of 44.3.

Roadmap: The company is opening showrooms in newer cities and growing its online jewellery arm. Strong brand recall and a franchise-led expansion model help it enter new regions at lower capital needs.

What to watch: Track same-store sales, new showroom additions and gold price movements.

Happiest Minds Technologies vs Anthem Biosciences vs Kalyan Jewellers India on Key Financials

The table below sets the three digital IT, drug research and jewellery stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Happiest Minds Technologies 1,131 2,400 20.7% 213 8.9%
Anthem Biosciences 1,280 2,280 15.5% 592 26.0%
Kalyan Jewellers India 10,856 35,951 34.9% 1,350 3.8%

Kalyan Jewellers India posts the highest return on equity in this group at 21.4%. Kalyan Jewellers India combines the largest FY26 revenue at Rs 35,951 crore with the fastest revenue growth, a 34.9% compound annual rate. A useful habit with digital IT, drug research and jewellery stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Digital IT, Drug Research and Jewellery Stocks

Every theme carries risks that deserve a check before any decision. For these digital IT, drug research and jewellery stocks, the main points are: Long-term digital engineering, contract research and gold jewellery shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Client spending. Technology budgets can vary with global conditions.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Pricing pressure. Generic prices can change by market.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter digital IT, drug research and jewellery stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Digital IT, Drug Research and Jewellery Stocks

Digital IT, drug research and jewellery stocks work best when investors track growth, valuation and return on equity side by side. Happiest Minds Technologies, Anthem Biosciences and Kalyan Jewellers India each have a clear plan to grow. Based on the 16 November 2026 close, Happiest Minds Technologies trades at Rs 308.5, Anthem Biosciences at Rs 931.45 and Kalyan Jewellers India at Rs 708.15. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these digital IT, drug research and jewellery stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track digital IT, drug research and jewellery stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are digital IT, drug research and jewellery stocks?

Ans. Digital IT, drug research and jewellery stocks are listed companies that build digital and cloud solutions for global clients, develop and manufacture drugs and biologics for pharma partners, and sell gold and diamond jewellery through large stores. Their earnings depend on client technology budgets, outsourced drug work and festive jewellery demand. This list looks at three of them, Happiest Minds Technologies, Anthem Biosciences and Kalyan Jewellers India, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.

Which digital IT, drug research and jewellery stocks are covered in this list?

Ans. This list covers Happiest Minds Technologies, Anthem Biosciences and Kalyan Jewellers India. Based on the 16 November 2026 close, Happiest Minds Technologies traded at Rs 308.5, Anthem Biosciences at Rs 931.45 and Kalyan Jewellers India at Rs 708.15. Their return on equity ranges from 12.6% to 21.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.5% to 34.9%.

Why do digital IT, drug research and jewellery stocks have a strong future roadmap in India?

Ans. Digital IT, drug research and jewellery stocks have a strong roadmap in India because rising digital projects, growing outsourcing of drug development and steady jewellery buying in festivals and weddings keep widening the market for these companies. The main drivers are as follows. Digital services. Clients modernise their systems. Drug research. Pharma firms outsource development work. Jewellery. Families buy gold for weddings and festivals. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Happiest Minds Technologies performed financially?

Ans. Revenue rose from Rs 1,131 crore in FY22 to Rs 2,400 crore in FY26, a compound annual growth rate of 20.7%. Net profit grew from Rs 185 crore in FY25 to Rs 213 crore in FY26, a rise of 15.1%. In the June 2026 quarter, revenue grew 12.5% year on year to Rs 652 crore, while net profit rose 18.3% to Rs 67.6 crore. The company has a return on equity of 12.6%, a debt to equity ratio of 0.88 and a market capitalisation of Rs 4,680 crore. The stock trades at a P/E of 21.0, above the industry P/E of 17.9. Looking ahead, the company is adding capabilities in artificial intelligence, cloud and cybersecurity, which enterprises are prioritising. A digital-first positioning helps it win newer projects from established clients.

How has Anthem Biosciences performed financially?

Ans. Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.

How has Kalyan Jewellers India performed financially?

Ans. Revenue rose from Rs 10,856 crore in FY22 to Rs 35,951 crore in FY26, a compound annual growth rate of 34.9%. Net profit grew from Rs 224 crore in FY22 to Rs 1,350 crore in FY26, which works out to a compound annual growth rate of 56.7%. In the June 2026 quarter, revenue grew 45.5% year on year to Rs 10,645 crore, while net profit rose 32.0% to Rs 349 crore. The company has a return on equity of 21.4%, a debt to equity ratio of 0.97 and a market capitalisation of Rs 52,898 crore. The stock trades at a P/E of 36.9, below the industry P/E of 44.3. Looking ahead, the company is opening showrooms in newer cities and growing its online jewellery arm. Strong brand recall and a franchise-led expansion model help it enter new regions at lower capital needs.

What risks should investors check before buying digital IT, drug research and jewellery stocks?

Ans. Investors should check a few risks before buying digital IT, drug research and jewellery stocks. Client spending. Technology budgets can vary with global conditions. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of digital IT, drug research and jewellery stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down